SeaStar Medical Holding Corporation

Equities

ICU

US81256L2034

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 01:30:00 22/06/2024 am IST			Pre-market 05:46:16 pm
7.21 ^USD	+36.55%		8.055	+11.72%

10/06	SeaStar Medical Holding Corporation Announces Board Changes	CI
04/06	SeaStar Medical Holding Corporation Approves Class II Director Appointments	CI

SeaStar Medical Holding Corporation Approves Class II Director Appointments

June 05, 2024 at 01:49 am IST

SeaStar Medical Holding Corporation at its special meeting of stockholders held on June 4, 2024, approved the appointment of Jennifer A. Baird and Bernadette N. Vincent as Class II Directors to serve until the 2027 annual meeting of stockholders, or until their successors shall have been duly elected and qualified.

Latest news about SeaStar Medical Holding Corporation

SeaStar Medical Holding Corporation Announces Board Changes	10/06	CI
SeaStar Medical Holding Corporation Approves Class II Director Appointments	05/06	CI
SeaStar Medical Holding Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05	CI
SeaStar Medical Announces $3.6 Million NIH Grant Award to Study the Selective Cytopheretic Device in Adult Patients with Severe Chronic Heart Failure	30/04	CI
SeaStar Medical Holding Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	17/04	CI
Seastar Medical Provides Updates on Enrollment of Adult Pivotal Clinical Study and Commercial Launch of Quelimmune, FDA-Approved in Pediatric Patients	12/03	CI
SeaStar Medical Receives FDA Approval for Pediatric Kidney Treatment Device	22/02	MT
SeaStar Medical Shares Rise 10% After FDA Humanitarian Device Exemption Approval	22/02	DJ
FDA Grants Humanitarian Device Exemption Approval to Seastar Medical?S Selective Cytopheretic Device for Pediatric Acute Kidney Injury	22/02	CI
SeaStar Medical Gets Canadian Patent Covering Technology for Cell-Directed Therapy	01/02	MT
Correction: SeaStar Medical Holding Prices $9 Million Registered Direct Stock Offering	26/01	MT
SeaStar Medical Holding Prices $9 Million Registered Direct Stock Offering	26/01	MT
SeaStar Medical Names David Green as Chief Financial Officer; Shares Rise After Hours	12/01	MT
SeaStar Medical Holding Corporation Announces Chief Financial Officer Changes	12/01	CI
SeaStar Enrolls Patients in Selective Cytopheretic Device Trial in Adults With Acute Kidney Injury	28/12	MT
SeaStar Medical Holding Corporation Updates Subject Enrollment in its Pivotal Trial with the Selective Cytopheretic Device in Adults with Acute Kidney Injury	28/12	CI
SeaStar Medical Forms Scientific Advisory Board of Pediatric and Adult Clinical Experts	13/12	CI
SeaStar Medical Holding Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	15/11	CI
SeaStar Medical Asked to Revise Product Label, Modify Study Plan for Medical Device Approval	31/23/31	MT
SeaStar Medical Shares Rise 13% After FDA Approvable Letter	30/23/30	DJ
Wall Street Set to Open Higher Monday as Investors Parse Earnings, Await Fed Meeting	30/23/30	MT
U.S. Food and Drug Administration Issues Approvable Letter for SeaStar Medical Holding Corporation's Selective Cytopheretic Device for Pediatric Patients	30/23/30	CI
Sector Update: Health Care Stocks Slip in Late Afternoon	28/23/28	MT
Sector Update: Health Care Stocks Retreating in Afternoon Trading	27/23/27	MT
Sector Update: Health Care	27/23/27	MT

Chart SeaStar Medical Holding Corporation

Duration

Period

Chart SeaStar Medical Holding Corporation

More charts

Company Profile

SeaStar Medical Holding Corporation is a commercial-stage medical technology company. The Company is focused on developing extracorporeal therapies to reduce the consequences of hyperinflammation on vital organs. The Company's technologies rely on science to provide life-saving solutions to critically ill patients. The Company develops and commercializes cell-directed extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company uses its Selective Cytopheretic Device (SCD) technology platform to clinically validate several acute organ injury indications, including kidneys and lungs. Its investigational SCD is an extracorporeal synthetic membrane device designed to integrate into existing continuous renal replacement therapy (CRRT) systems that are commonly installed in hospitals throughout the United States.

Sector

Medical Equipment, Supplies & Distribution

Calendar

12/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

7.21 USD

Average target price

50 USD

Spread / Average Target

+593.48%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Equipment

	1st Jan change	Capi.
SEASTAR MEDICAL HOLDING CORPORATION	-34.85%	3.85Cr
SHOCKWAVE MEDICAL	+75.69%	1.26TCr
MASIMO CORPORATION	+11.91%	696.32Cr
PENUMBRA, INC.	-29.01%	692.19Cr
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.	+9.77%	523.85Cr
GETINGE AB	-19.55%	460.19Cr
APT MEDICAL INC.	+13.02%	402.44Cr
ASAHI INTECC CO., LTD.	-21.91%	376.51Cr
INARI MEDICAL, INC.	-29.14%	267.44Cr
NOVOCURE LIMITED	+27.73%	205.21Cr

Medical Equipment